ClinicalTrials.gg
CompletedNCT02276027Updated Dec 16, 2020Results posted

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

A Phase 2 interventional study of BYL719 and INC280 in Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Adenocarcinoma of Lung by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Adenocarcinoma of Lung · Novartis.

Enrollment
8th of 13
66 · median 124
Started
2015
with 2 others
Phase 2
9 of 16
none open now
Registered
7th of 16
by date

Among the 16 studies in Adenocarcinoma of Lung by Novartis, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2015, is one of 9 in phase 2, and was the 7th registered.

Adenocarcinoma of Lung

418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.

Browse Adenocarcinoma of Lung studies →

Open to participants now

1 of the 16 studies in Adenocarcinoma of Lung by Novartis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 58 Adenocarcinoma of Lung studies recruiting now, 36 (62%) set no upper age limit and 10 (17%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Adenocarcinoma of Lung by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162 in advanced NSCLC patients carrying specific molecular alterations.

There is a great unmet medical need in NSCLC patients with advanced or metastatic disease. Novel approaches using targeted therapeutic agents for these patient populations with molecular characterization could potentially identify subsets of advanced NSCLC patients who would benefit from targeted kinase inhibition. Study treatments, BYL719, INC280, LDK378 and MEK162, which target PIK3CA, c-MET, ALK/ROS1 and MEK respectively, have shown promising data in either preclinical or clinical lung cancer settings.

Read the detailed description

To enter the screening phase of the study, the subjects' molecular alterations were determined using locally validated methodologies from a newly obtained tumor sample (preferred) or the most recent archival tumor sample available. Based on the molecular alterations of the tumor, subjects were assigned to one of the treatment arms. Subjects with multiple molecular alterations in epidermal growth factor receptor (EGFR) and the relevant pathways were excluded, except under the conditions described in Inclusion criteria.

The treatment period began on Cycle 1 Day 1 and continued in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of informed consent, death or the subject transferred to another Novartis study that could continue to provide the study drug.

All subjects were required to be followed up for 30 days for safety after receiving the last dose of study treatment. Subjects who discontinued study treatment for any reason other than disease progression were followed up for progression of disease. All subjects were required to be followed for survival. For subjects transferred to another Novartis study, an end of treatment visit (EOT) was required to be performed and the subject would not enter the follow-up period.

03

Conditions studied

  • Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma

Keywords

  • adenocarcinoma lung cancer,
  • squamous cell lung carcinoma,
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced (stage IIIB or stage IV) NSCLC
  • Must have specific molecular alterations

Exclusion criteria

Exclusion Criteria:

  • Symptomatic central nervous system (CNS) which are neurologically unstable or requiring increasing doses of within the 4 weeks prior to study entry to control their CNS disease
  • Radiation therapy within ≤ 4 weeks prior to study entry, with the exception of limited field palliative radiotherapy for bone pain relief.
  • Any other within the last 5 years before study entry
  • Major surgery ≤ 2 weeks prior to study entry or who have not recovered from side effects of such therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    BYL719 350 mg QD

    Patient's tumor must have molecular alteration of the PIK3CA gene.

    Drug: BYL719

  • Experimental
    INC280 400 mg BID tab/600 mg BID cap

    Patient's tumor must have molecular alteration of the c-MET gene.

    Drug: INC280

  • Experimental
    LDK378 750 mg QD

    Patient's tumor must have ALK or ROS1 gene rearrangement.

    Drug: LDK378

  • Experimental
    MEK162 45 mg BID

    Patient's tumor must have KRAS, NRAS or BRAF mutation.

    Drug: MEK162

Interventions

  • DrugBYL719

    BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.

  • DrugINC280

    INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.

  • DrugLDK378

    LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.

  • DrugMEK162

    MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall response rate is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (Overall Response (OR) = CR + PR). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to 231 weeks

Secondary outcomes

  1. Median Overall Survival (OS)

    OS is defined as the time from date of randomization/start of treatment to date of death due to any cause.

    Time frame: Up to 231 weeks

  2. Number of Participants With Progression-free Survival (PFS)

    PFS event is defined as the first documented progression or death due to any cause according to RECIST 1.1 criteria

    Time frame: Up to 231 weeks

  3. Disease Control Rate (DCR)

    DCR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR) or Stable Disease (SD) according to RECIST 1.1 criteria (DCR: CR+PR+SD) Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD

    Time frame: Up to 231 weeks

  4. Median Duration of Overall Response (DOR)

    Duration of overall response (DOR) is defined as the time from the first documented CR or PR (confirmed by the subsequent assessment) to the date of the first documented progression or death due to underlying cancer.

    Time frame: Up to 231 weeks

  5. Number of Participants With Adverse Events

    Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life-threatening, corresponding to grades 1 - 4, was used.

    Time frame: up to 235 weeks

  6. Pharmacokinetics Profile, AUCtau and AUClast

    PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). AUCtau is the AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1) AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)

  7. Pharmacokinetics Profile, Cmax

    PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Cmax is the maximum (peak) observed plasma concentration (mass x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)

  8. Pharmacokinetics Profile, Tmax

    PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Tmax is the time to reach maximum (peak) plasma concentration (time) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)

07

Results

Posted Dec 16, 2020

Participant flow

Participants were from China

Participant flow — Overall Study
MilestoneBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Started2162622
Completed0060
Not completed2162022
Withdrew: Death1002
Withdrew: Physician decision0001
Withdrew: Progressive disease1131214
Withdrew: Subject/guardian decision0103
Withdrew: Adverse event0282

Outcome measures

PrimaryOverall Response Rate (ORR)

Overall response rate is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (Overall Response (OR) = CR + PR). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to 231 weeks
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Overall Response Rate (ORR)03192
SecondaryMedian Overall Survival (OS)

OS is defined as the time from date of randomization/start of treatment to date of death due to any cause.

Time frame:
Up to 231 weeks
Reported as:
Median · Months
Median Overall Survival (OS)
MonthsBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Median Overall Survival (OS)4.99 (0.30 to 9.69)13.26 (1.18 to 23.33)NA (19.35 to NA)9.20 (3.52 to 11.93)
SecondaryNumber of Participants With Progression-free Survival (PFS)

PFS event is defined as the first documented progression or death due to any cause according to RECIST 1.1 criteria

Time frame:
Up to 231 weeks
Reported as:
Count of participants · Participants
Number of Participants With Progression-free Survival (PFS)
ParticipantsBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Number of Participants With Progression-free Survival (PFS)2161919
SecondaryDisease Control Rate (DCR)

DCR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR) or Stable Disease (SD) according to RECIST 1.1 criteria (DCR: CR+PR+SD) Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD

Time frame:
Up to 231 weeks
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Disease Control Rate (DCR)50.0 (1.3 to 98.7)43.8 (19.8 to 70.1)92.3 (74.9 to 99.1)59.1 (36.4 to 79.3)
SecondaryMedian Duration of Overall Response (DOR)

Duration of overall response (DOR) is defined as the time from the first documented CR or PR (confirmed by the subsequent assessment) to the date of the first documented progression or death due to underlying cancer.

Time frame:
Up to 231 weeks
Reported as:
Median · Months
Median Duration of Overall Response (DOR)
MonthsBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Median Duration of Overall Response (DOR)—3.84 (3.81 to 5.59)34.96 (7.59 to NA)5.47 (3.55 to 7.39)
SecondaryNumber of Participants With Adverse Events

Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life-threatening, corresponding to grades 1 - 4, was used.

Time frame:
up to 235 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
AE All grades2162622
AE Grade 3/41112320
SAE All grades1121118
SAE Grade 3/417915
SecondaryPharmacokinetics Profile, AUCtau and AUClast

PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). AUCtau is the AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1) AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)
Reported as:
Mean · ng*h/mL
Pharmacokinetics Profile, AUCtau and AUClast
ng*h/mLBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
AUClast Cycle 1 Day 120909 ± 107———
AUCtau Cycle 1 Day 1523892 ± NA32034 ± 699230361 ± 38072645 ± 981
AUClast Cycle 1 Day 1523721 ± NA27875 ± 762928013 ± 50062642 ± 1026
SecondaryPharmacokinetics Profile, Cmax

PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Cmax is the maximum (peak) observed plasma concentration (mass x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)
Reported as:
Mean · ng/mL
Pharmacokinetics Profile, Cmax
ng/mLBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Cmax Cycle 1 Day 12135 ± 700———
Cmax Cycle 1 Day 152630 ± NA8046 ± 35501362 ± 177587 ± 183
SecondaryPharmacokinetics Profile, Tmax

PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Tmax is the time to reach maximum (peak) plasma concentration (time) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)
Reported as:
Median · hours
Pharmacokinetics Profile, Tmax
hoursBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
Tmax Cycle 1 Day 14.03 (2.05 to 6.00)———
Tmax Cycle 1 Day 152.00 (2.00 to 2.00)1.00 (0.467 to 6.17)6.10 (2.03 to 8.00)1.10 (0.517 to 7.58)

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days after receiving the last dose of study treatment, up to maximum duration of 235 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYL719 350 mg QD1/2 (50%)1/2 (50%)2/2 (100%)
INC280 400 mg BID Tab/600 mg BID Cap4/16 (25%)12/16 (75%)16/16 (100%)
LDK378 750 mg QD1/26 (3.8%)11/26 (42.3%)26/26 (100%)
MEK162 45 mg BID5/22 (22.7%)18/22 (81.8%)22/22 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
DyspnoeaRespiratory, thoracic and mediastinal disorders1/25/161/264/22
PneumoniaInfections and infestations0/22/163/264/22
Blood creatine phosphokinase increasedInvestigations0/20/160/264/22
PyrexiaGeneral disorders0/21/160/263/22
Pleural effusionRespiratory, thoracic and mediastinal disorders0/22/161/263/22
HyperglycaemiaMetabolism and nutrition disorders0/20/162/260/22
HyperuricaemiaMetabolism and nutrition disorders0/20/162/260/22
AstheniaGeneral disorders0/21/160/261/22
Non-cardiac chest painGeneral disorders0/21/160/260/22
AtelectasisRespiratory, thoracic and mediastinal disorders0/21/160/260/22
Most frequent other events
Showing 10 of 231
Most frequent other events
EventBYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BID
DiarrhoeaGastrointestinal disorders0/24/1626/2614/22
Aspartate aminotransferase increasedInvestigations1/25/1626/2616/22
HypoalbuminaemiaMetabolism and nutrition disorders2/214/1621/2613/22
Alanine aminotransferase increasedInvestigations0/27/1624/266/22
AnaemiaBlood and lymphatic system disorders0/213/1619/2618/22
Abdominal pain upperGastrointestinal disorders0/22/1620/263/22
VomitingGastrointestinal disorders0/26/1620/269/22
Blood creatine phosphokinase increasedInvestigations0/22/167/2616/22
RashSkin and subcutaneous tissue disorders0/20/1612/2616/22
HyperuricaemiaMetabolism and nutrition disorders1/25/1617/264/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)BYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BIDTotal
Mean53.0 (44 to 62)58.2 (47 to 65)49.4 (33 to 66)60.3 (48 to 74)55.3 (33 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)BYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BIDTotal
Female0515323
Male211111943
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)BYL719 350 mg QDINC280 400 mg BID Tab/600 mg BID CapLDK378 750 mg QDMEK162 45 mg BIDTotal
Count of participants————0
08

Study locations

1 site
  • Novartis Investigative Site
    Guangzhou, Guangdong 51000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Oct 2019, 56 months.

Results were first posted in Dec 2020, 1 year 2 months after primary completion.

Of 53 phase 2 interventional studies under Adenocarcinoma of Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2014
First posted
Oct 27, 2014
StartActual
Jan 20, 2015
Primary completionActual
Oct 15, 2019
CompletionActual
Oct 15, 2019
Results first posted
Dec 16, 2020
Last update
Dec 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02276027
Responsible party
Sponsor
First posted
Oct 27, 2014
Start date
Jan 20, 2015
Primary completion
Oct 15, 2019
Completion
Oct 15, 2019
Results posted
Dec 16, 2020
Last update
Dec 16, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Capmatinib · Ceritinib · Binimetinib

Start the discussion